07 July 2015

HIV vaccine: another hope

Experimental vaccine protects monkeys from HIV-like virus


The authors of the study called the results "promising".

According to data presented in the journal Science (Barouch et al., Protective efficacy of adenovirus-protein vaccines against SIV challenges in rhesus monkeys – VM), the two-stage vaccine caused the formation of antibodies against the virus. Measuring the concentration of antibodies allowed scientists to evaluate the effectiveness of the drug, which protected six out of 12 animals from infection. "We don't know if the vaccine will be able to protect a person, but it seems to me that it is possible," said Dan Barouch, the head of the study. He explained that scientists plan to study the effect of the HIV vaccine. In addition, the authors of the study analyzed the effectiveness of immunization in the case when monkeys were infected with the combined HIV-SIV virus. It turned out that the vaccine protected 40% of animals from infection.

The main difficulty that scientists face when creating a vaccine against HIV is that the virus infects the cells that the body produces to fight infection – CD4+ T cells. When creating a new type of vaccine, scientists used adenovirus 26, which causes the common cold. When it spreads through the body, the immune response is activated. At the second stage, a drug containing HIV particles was injected. This contributed to the launch of the production of antibodies against the virus.

Another team of scientists is testing a vaccine in the form of tablets for oral use. "I think their results are impressive. Protecting even half of the people who are exposed to the virus will be a great achievement. In combination with other measures, this will put an end to the epidemic," said Mary Marovich, an employee of the National Institute for the Study of Allergy and Infectious Diseases.

Portal "Eternal youth" http://vechnayamolodost.ru
07.07.2015
Found a typo? Select it and press ctrl + enter Print version